Merck & Co.
AWARDS
NEWS
This is the second such biomarker-specific approval for Keytruda. The first biomarker-specific approval came in 2017.
It was a fairly busy week with clinical trial updates and announcements. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 12, 2020.
KEYNOTE-361 is evaluating Keytruda alone and in combination with chemotherapy compared to chemotherapy alone, the current standard of care, for first-line treatment of advanced or metastatic urothelial carcinoma.
The next two weeks are busy ones for the U.S. Food and Drug Administration (FDA). Here’s a look at PDUFA dates for this period.
Less than one month after the White House zeroed in on 14 vaccine candidates for COVID-19, the administration has narrowed that list even more to five potential treatments for the prevention of the novel coronavirus.
JOBS
IN THE PRESS